Orforglipron (Foundayo) comes as six tablets: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg. You start on 0.8 mg once a day, move to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 more. From there the dose can go up to 9, 14.5 and 17.2 mg, again with at least 30 days on each, if it is needed and tolerated. 17.2 mg is the maximum. It is one tablet a day, at any time, with or without food. There is nothing to mix or measure, so unlike injectable GLP-1s there are no syringe units to work out.
The FDA approved orforglipron as Foundayo (Eli Lilly) on April 1, 2026, for weight management in adults with obesity, or overweight plus a weight-related condition. It is the first GLP-1 medicine that is a small molecule rather than a peptide, which is why it survives the stomach without the fasting rules other GLP-1 pills need.
Foundayo dosage chart
| Tablet | Earliest step | Looks like | Imprint | Self-pay price / month |
|---|---|---|---|---|
| 0.8 mg | Start (month 1) | Pink, round | L / G1 | $149 |
| 2.5 mg | Month 2 or later | Light yellow, round | L / G2 | $199 |
| 5.5 mg | Month 3 or later | Grayish purple, round | L / G3 | $299 |
| 9 mg | Optional, month 4+ | Pink, oval | Lilly / G4 | $299 |
| 14.5 mg | Optional, month 5+ | Light yellow, oval | Lilly / G5 | $299* |
| 17.2 mg | Optional, month 6+ (maximum) | Grayish purple, oval | Lilly / G6 | $299* |
“Month 2 or later” means each step comes after at least 30 days on the previous dose. Your prescriber may keep you on a lower dose longer; the label lets the top three steps depend on how you respond and how well you tolerate it. Prices are LillyDirect self-pay prices; *14.5 and 17.2 mg are $299 if you refill within 45 days, otherwise $349. With commercial insurance and Lilly’s savings card it can be as little as $25 a month. Prices change, so check before you order.
Why news stories mention 12 mg and 36 mg
The big trials used an earlier capsule form at 1, 3, 6, 12, 24 and 36 mg. The tablets you can buy are a different formulation, and Lilly states that each capsule dose gives the same blood levels as a smaller tablet dose. So “36 mg orforglipron” in a news story is the same as today’s 17.2 mg tablet, not twice as much.
| Capsule dose in trials | Same exposure as tablet |
|---|---|
| 1 mg | 0.8 mg |
| 3 mg | 2.5 mg |
| 6 mg | 5.5 mg |
| 12 mg | 9 mg |
| 24 mg | 14.5 mg |
| 36 mg | 17.2 mg |
How much weight people lost at each dose
From the prescribing information, after 72 weeks, counting everyone who started (including people who stopped taking it):
| Dose | Average weight change | Lost ≥10% | Lost ≥15% | With type 2 diabetes: average change |
|---|---|---|---|---|
| Placebo | −2.1% | 13% | 6% | −2.5% |
| 5.5 mg (trial 6 mg) | −7.4% | 32.5% | 14.3% | −5.1% |
| 9 mg (12 mg) | −8.3% | 39.8% | 20.1% | −7% |
| 17.2 mg (36 mg) | −11.1% | 54.5% | 35.9% | −9.6% |
Trial doses are shown in brackets. The 11.1% figure is lower than the roughly 12% quoted in some headlines because it includes people who stopped treatment. The results come from adults also following diet and activity advice.
Side effects by dose
As with all GLP-1 drugs, the common side effects are in the gut, and they are why the dose goes up slowly:
| Side effect | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Indigestion | 4% | 12% | 16% | 13% |
Other side effects seen in at least 5% of people were stomach pain, headache, bloating, tiredness, burping, reflux and wind. Like other GLP-1 medicines, Foundayo carries a boxed warning about thyroid C-cell tumours seen in rodents, and should not be used by anyone with a personal or family history of medullary thyroid cancer or MEN 2. Lilly notes that orforglipron is not active in rats or mice and did not cause these tumours in them.
Rules on the label
- One tablet a day, swallowed whole. Do not split, crush or chew it.
- Missed a dose? Take it as soon as you remember, but never two on one day.
- Missed 7 days or more in a row? Ask your prescriber; the label says to restart at a lower dose and step up again, because jumping straight back to a high dose brings on stomach side effects.
- The pill (oral contraceptive): switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each step up.
- Some other medicines change the dose. With strong CYP3A4 inhibitors (for example some antifungals and HIV drugs) the maximum is 9 mg, and some should be avoided altogether. Strong CYP3A4 inducers such as rifampin should be avoided.
- Do not combine with another GLP-1 medicine.
- Kidneys and liver: no dose change for kidney problems; not recommended with severe liver impairment.
Switching from injections
The label gives no switching schedule, but the ATTAIN-MAINTAIN trial tested exactly this. People who had lost weight over 72 weeks on the highest dose of Wegovy or Zepbound they could tolerate switched straight to daily orforglipron. A year later, the Wegovy group weighed on average 95.9 kg, against 95.0 kg at the switch (+0.9 kg). The Zepbound group went from 90.9 kg to 95.9 kg (+5.0 kg). People switched to placebo regained much more. So orforglipron held most of the loss after semaglutide and part of it after tirzepatide. How to switch is a decision for your prescriber.
Foundayo vs the Wegovy pill
| Foundayo (orforglipron) | Wegovy pill (oral semaglutide) | |
|---|---|---|
| What it is | Small molecule, not a peptide | Peptide with an absorption enhancer |
| Strengths | 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg | 1.5, 4, 9, 25 mg |
| Steps | Every 30+ days; top three steps optional | Every 30 days up to 25 mg |
| How to take | Any time, with or without food or water | Morning, empty stomach, up to 4 oz (120 mL) of water, then wait 30 minutes |
The two pills have not been compared head to head in a trial, so their weight-loss figures cannot be lined up fairly. The practical difference is the routine: Foundayo has no timing rules. For the injectable options, see our GLP-1 dosage chart.
Storage
Foundayo comes in bottles of 30 tablets with a desiccant. Keep it at room temperature, 20–25 °C (68–77 °F); short spells between 15 and 30 °C (59–86 °F) are fine. It does not need the fridge.
Where things stand (November 2026)
- US: approved for weight management in April 2026; a separate application for type 2 diabetes is with the FDA.
- EU: on 15 October 2026 the EMA’s committee recommended approval for weight management and type 2 diabetes; the European Commission makes the final decision.
- Sleep apnoea: on 9 November 2026 Lilly reported positive trial results in obstructive sleep apnoea and plans to file with the FDA by the end of 2026.
Is there an orforglipron calculator?
For the tablets, no calculation is needed: the strength is printed on the bottle. Our orforglipron calculator exists because orforglipron is also sold online as “research” powder. That powder is not checked by any regulator, its strength and purity are unknown, and it is not Foundayo. If you are comparing it with injectable drugs, the semaglutide and tirzepatide charts show those doses in syringe units.
Sources: Foundayo prescribing information (dosing, results, side effects, storage); Lilly Medical: capsule vs tablet doses; LillyDirect prices; Lilly: ATTAIN-MAINTAIN results; EMA: Foundayo opinion; Lilly: sleep apnoea results.

